|Articles|June 23, 2003

CEL-SCI Signs Agreement With National Institutes of Health and U.S. Army for Testing of CEL-1000 Against SARS, Smallpox, Vaccinia and West Nile Virus

VIENNA, Va. -- CEL-SCI Corporation has signed a cooperative agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health, and the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) to test CEL-SCI's proprietary CEL-1000 peptide against SARS, smallpox, vaccinia, West Nile virus and potentially several other diseases as well. The testing will be conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventive agent against these diseases.

CEL-1000 has been shown in separate studies to be protective in animal models against herpes and malaria, and to enhance survival against cancer in animals. CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad-spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents.

Two research grants have recently been awarded for CEL-1000 by the U.S. government. In April 2003, Northeastern Ohio Universities College of Medicine (NEOUCOM) was awarded a $1.1 million grant for collaborative studies with CEL- SCI to develop CEL-1000 as a possible treatment for viral encephalitis. Viral encephalitis is a potentially lethal inflammation of the brain. In May 2003, CEL-SCI was awarded a $162,000 SBIR Phase I grant to further the development of CEL-1000 against herpes simplex.

Geert Kersten, CEO of CEL-SCI said, "We are very pleased with the support we have been receiving from the U.S. government and for assisting our efforts to improve patients' lives by testing CEL-1000 as a novel treatment for a wide range of diseases."

CEL-1000 is a modified version of a human immune-based-protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases.

Source: CEL-SCI Corporation


Related to this article

Infection preventionists in full PPE with children in DRC.  (Image credit: author with AI)
Nearly 4 months into the DRC's Bundibugyo virus disease outbreak, some indicators suggest transmission may be slowing. But shifting hotspots, treatment-center capacity problems, community deaths, and incomplete surveillance data show why national case totals alone cannot determine whether containment has been achieved.
Health care workers from the US speaking with other health care workers in DRC.  (Image credit: author with AI)
Is the Ebola outbreak in the DRC getting better? The answer depends on which numbers you examine. Several important indicators are moving in the right direction, including slower case growth and a declining Rₜ. But major gaps remain in contact tracing, testing, community deaths, safe burial coverage, and treatment capacity in some of the hardest-hit areas. ICT takes a deeper look at the latest outbreak data and why the numbers suggest cautious optimism, not victory.
Dyan Troxell, MSN, RN, director of clinical education at HandCraft Linen Services; J.J. Odom, MBA, CHESP, CMIP, T-CHEST, university director of buildings and grounds for UConn Health and chair-elect of the AHE Board; and Jenna Rivers, MPH, CPH, CIC, manager of infection prevention and control at Moffitt Cancer Center in Tampa, Florida.
At AHE Exchange 2026, ICT spoke with experts representing commercial laundry services, EVS, and infection prevention about the systems behind a successful reusable linen program. They discuss linen quality, reject rates, unnecessary waste, frontline education, data, PAR levels, infection prevention oversight, and why strong relationships between health care facilities and their laundry providers matter.
A group of students raising their hands in class during a lecture  (Adobe Stock 292282454 by Mediteraneo
How do you celebrate an infection that never happened? That's one of the unusual challenges infection preventionists share with teachers. Both can spend their careers changing outcomes they may never see. Both educate people who don't always want to listen. Both are second-guessed. Both face burnout. And both must somehow keep remembering why they started.